利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.019 秒)

    Apparatus and method for transdermal delivery of bupropion
    2.
    发明授权
    Apparatus and method for transdermal delivery of bupropion 失效
    用于经皮递送安非他酮的装置和方法

    公开(公告)号：US06280763B1

    公开(公告)日：2001-08-28

    申请号：US09309075

    申请日：1999-05-10

    申请人： Kamal K. Midha ,  Hans E. Junginer ,  Mark Hirsh

    发明人： Kamal K. Midha ,  Hans E. Junginer ,  Mark Hirsh

    IPC分类号： A61F1302

    CPC分类号： A61K9/7023 ,  A61K31/137 ,  A61K47/12 ,  A61K47/14 ,  A61K47/22

    摘要： The invention includes an apparatus and method for transdermal delivery of bupropion base. In the method of this invention, patient is administered parenterally a bupropion base in an amount effective to alleviate withdrawal symptoms and to prevent or reduce craving of nicotine in said patient. Alternatively, an effective amount of bupropion base is delivered to alleviate depression in a patient. A transdermal delivery system includes a bupropion base. The bupropion base can be mixed with an acceptable pharmaceutical carrier.

    摘要翻译： 本发明包括用于安非他酮碱的透皮递送的装置和方法。 在本发明的方法中，患者以有效缓解戒断症状并预防或减少所述患者中尼古丁的渴望的量肠胃外施用安非他酮碱。 或者，输送有效量的安非他酮碱以缓解患者的抑郁症。 透皮递送系统包括安非他酮碱。 安非他酮碱可与可接受的药物载体混合。

    ATOMOXETINE FORMULATIONS AND ASSOCIATED METHODS
    3.
    发明申请
    ATOMOXETINE FORMULATIONS AND ASSOCIATED METHODS 审中-公开
    阿托莫司汀配方及相关方法

    公开(公告)号：US20080145318A1

    公开(公告)日：2008-06-19

    申请号：US11610330

    申请日：2006-12-13

    申请人： Kamal K. Midha

    发明人： Kamal K. Midha

    IPC分类号： A61K31/135 ,  A61K31/439 ,  A61K9/70 ,  A61K9/12

    CPC分类号： A61K31/135 ,  A61K9/0014 ,  A61K9/06 ,  A61K9/4875 ,  A61K9/7061 ,  A61K31/439

    摘要： Methods and formulations for delivering atomoxetine compounds that minimize drug metabolism and thus increase the effectiveness of the drug are disclosed. The in vivo potency of the atomoxetine compound may be maximized by minimizing the in vivo conversion of the atomoxetine compound to an atomoxetine compound metabolite.

    摘要翻译： 公开了用于递送阿托莫西汀化合物的方法和制剂，其最小化药物代谢并因此增加药物的有效性。 通过最小化阿托莫西汀化合物与阿托西汀化合物代谢物的体内转化，可以使阿托莫西汀化合物的体内效力最大化。

    Transdermal atomoxetine formulations and associated methods
    4.
    发明申请
    Transdermal atomoxetine formulations and associated methods 审中-公开
    透皮阿托西汀制剂及相关方法

    公开(公告)号：US20080031932A1

    公开(公告)日：2008-02-07

    申请号：US11499912

    申请日：2006-08-04

    申请人： Kamal K. Midha

    发明人： Kamal K. Midha

    IPC分类号： A61K31/138 ,  A61K9/70

    CPC分类号： A61K9/7061 ,  A61K9/06 ,  A61K31/138

    摘要： Methods and formulations for delivering atomoxetine compounds that minimize drug metabolism and thus increase the effectiveness of the drug are disclosed. The method may include maximizing the in vivo potency of an atomoxetine compound in a subject by transdermally administering the atomoxetine compound to the subject. The in vivo potency of the atomoxetine compound may be maximized by minimizing the in vivo conversion of the atomoxetine compound to an atomoxetine compound metabolite.

    摘要翻译： 公开了用于递送阿托莫西汀化合物的方法和制剂，其最小化药物代谢并因此增加药物的有效性。 该方法可以包括通过向受试者透皮施用阿托莫西汀化合物来最大化受试者中阿托莫西汀化合物的体内效力。 通过最小化阿托莫西汀化合物与阿托西汀化合物代谢物的体内转化，可以使阿托莫西汀化合物的体内效力最大化。

    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
    5.
    发明授权
    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent 失效

    公开(公告)号：US06645524B2

    公开(公告)日：2003-11-11

    申请号：US09929838

    申请日：2001-08-14

    申请人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    发明人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K956

    CPC分类号： A61K9/5084 ,  A61K9/2081 ,  A61K9/209

    摘要： Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.

    Pharmaceutical composition containing two active ingredients for smoking cessation
    6.
    发明授权
    Pharmaceutical composition containing two active ingredients for smoking cessation 失效
    含有两种戒烟活性成分的药物组合物

    公开(公告)号：US06582737B2

    公开(公告)日：2003-06-24

    申请号：US09962927

    申请日：2001-09-25

    申请人： Mark Hirsh ,  Kamal K. Midha ,  Hans E. Junginger

    发明人： Mark Hirsh ,  Kamal K. Midha ,  Hans E. Junginger

    IPC分类号： A61K3578

    CPC分类号： A61K9/703 ,  A61K9/7084 ,  A61K9/7092 ,  A61K31/135 ,  A61K31/465 ,  A61K31/505 ,  A61K2300/00

    摘要： A kit to alleviate tobacco-smoking withdrawal symptoms in a patient is disclosed which comprises: (a) a therapeutically effective amount of nicotine, at least one active nicotine metabolite, a combination of nicotine and an active nicotine metabolite, or an azapirone, or a pharmaceutically acceptable salt thereof; (b) a transdermal delivery system consisting essentially of a bupropion base in a therapeutically effective amount; and (c) a packaging material surrounding (a) and (b).

    摘要翻译： 公开了一种用于减轻患者戒烟戒烟症状的试剂盒，其包括：（a）治疗有效量的尼古丁，至少一种活性尼古丁代谢物，尼古丁和活性尼古丁代谢物的组合，或氮杂氮酮，或 其药学上可接受的盐;（b）基本上由治疗有效量的安非他酮碱组成的透皮递送系统; （c）围绕（a）和（b）的包装材料。

    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
    7.
    发明授权
    Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent 失效

    公开(公告)号：US06500457B1

    公开(公告)日：2002-12-31

    申请号：US09639584

    申请日：2000-08-14

    申请人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    发明人： Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K920

    CPC分类号： A61K9/5084 ,  A61K9/2081 ,  A61K9/209

    摘要： Novel pharmaceutical dosage forms provide for pulsatile delivery of an antiarrhythmic agent that releases the drug in spaced apart “pulses.” The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. The dosage forms may comprise capsules housing compressed tablets or drug-containing beads, granules, or particles or may comprise a single tablet with the first, second and optional third dosage units incorporated therein, or a “coated core” dosage form. Methods of treatment using the pharmaceutical dosage forms are provided as well.

    Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
    8.
    发明授权
    Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration 失效
    用于口内和口服给药的具有模制的triturate片剂的压缩环形片剂的药物组合物

    公开(公告)号：US07387792B2

    公开(公告)日：2008-06-17

    申请号：US11041474

    申请日：2005-01-24

    申请人： Jane C. Hirsh ,  Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    发明人： Jane C. Hirsh ,  Kamal K. Midha ,  Mark Hirsh ,  Whe-Yong Lo

    IPC分类号： A61K9/20 ,  A61K9/22 ,  A61K9/24 ,  A61K9/46

    CPC分类号： A61K9/209 ,  A61K9/0056

    摘要： New pharmaceutical compositions in unit dosage form are disclosed for both intraoral and oral administration to a patient, said unit dosage form configured to be placed intraorally of said patient, which comprises: (a) as a first portion, at least one discrete molded triturate tablet comprising a therapeutically effective amount of at least one pharmaceutically active ingredient capable of intraoral administration; and (b) as a second portion located around the said first portion, a therapeutically effective amount of at least one pharmaceutically active ingredient capable of oral administration and which is releasable and orally ingestible by the patient after the molded triturate tablet has disintegrated or has dissolved intraorally.

    摘要翻译： 公开了单位剂量形式的新的药物组合物，用于向患者进行口内和口服给药，所述单位剂型被配置为置于所述患者的口内，其包括：（a）作为第一部分，至少一个离散的模制成型的片剂 包括治疗有效量的至少一种能口内给药的药物活性成分; 和（b）作为位于所述第一部分周围的第二部分，治疗有效量的至少一种能够口服给药的药学活性成分，并且其在模制的特定片剂崩解或溶解之后由患者可释放和口服摄入 口语